Charleville Mezieres

Researchers are investigating the use of high-dose intravenous vitamin C combined with thiamine vitamin B1 to manage post-cardiac arrest shock in patients admitted to intensive care units after out-of-hospital cardiac arrest. This condition often leads to cardiac and circulatory failure, causing multi-organ failure and early death in a significant portion of patients. The study is a phase II, multicenter, randomized controlled trial comparing standard care with the addition of high-dose vitamin C and thiamine to assess potential benefits on shock recovery and neurological outcomes. Participants are randomly assigned to one of two groups the control group receiving standard post-cardiac arrest care according to international guidelines, and the experimental group receiving standard care plus high-dose intravenous vitamin C at 50 mgkg every 6 hours for 3 days, starting within an hour after randomization, along with intravenous thiamine 200 mg twice daily for 3 days. From day 4 onwards, standard vitamin C supplementation up to 1000 mg daily and thiamine are allowed in both groups. During the 28-day participation period, patients will be closely monitored for recovery from shock, neurological function, and organ failure. Assessments include measuring the time to stop vasopressors by day 3, survival rates related to shock by day 7, neurological status at day 28, maximum vasopressor doses within 3 days, changes in organ failure scores, and arterial lactate levels. Safety and effectiveness data will be collected throughout to evaluate the impact of the vitamin C and thiamine treatment alongside standard care.

Researchers are evaluating whether giving amiodarone for 72 hours can reduce deaths and severe heart rhythm problems within 30 days in critically ill adults admitted after an out-of-hospital cardiac arrest with an initial shockable heart rhythm and a confirmed or suspected cardiac cause. This phase 3 trial is randomized and compares patients receiving amiodarone to those receiving no intervention. The study is sponsored by Versailles Hospital. Participants in the amiodarone group receive an initial 300 mg loading dose over 30 minutes, followed by a continuous infusion for 72 hours at 10 mgkg per day, not exceeding 900 mg per 24 hours. The control group does not receive amiodarone. Treatment starts shortly after admission to intensive care and screening. The study measures outcomes for up to 90 days, including heart-related events, mortality, ventilation duration, neurological status, vasopressor use, and hospital stay length. During the study, patients are closely monitored in intensive care with regular assessments of their heart condition and overall health. Researchers track serious ventricular arrhythmias and death rates over 30 days as the main outcome. Secondary outcomes include longer-term cardiac events, neurological outcomes, and side effects related to amiodarone within 5 days. The total follow-up lasts up to 90 days, during which participants responses to treatment and safety are carefully observed.